---
document_datetime: 2024-10-14 10:03:15
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/deferasirox-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: deferasirox-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.6118581
conversion_datetime: 2025-12-28 03:51:44.035874
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Deferasirox Mylan

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                         |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0013               | Renewal of the marketing authorisation. | 30/05/2024                          | 22/07/2024                                  | SmPC, Annex II and PL            | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Deferasirox Mylan in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/939/2 02210   | Periodic Safety Update EU Single assessment - deferasirox                                                                                                                                                                                                    | 08/06/2023   | n/a        |                  | PRAC Recommendation - maintenance   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------|-------------------------------------|
| IB/0011             | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 17/02/2023   | 17/03/2023 | SmPC             |                                     |
| IB/0010             | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 04/01/2023   | 17/03/2023 | SmPC and PL      |                                     |
| IB/0009             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                | 22/04/2022   | n/a        |                  |                                     |
| IB/0007             | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 03/12/2021   | 28/11/2022 | Labelling and PL |                                     |
| IA/0008             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                   | 24/11/2021   | n/a        |                  |                                     |

<div style=\"page-break-after: always\"></div>

| T/0006      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 12/08/2021   | 01/09/2021   | SmPC, Labelling and PL   |                                     |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-------------------------------------|
| IAIN/0005/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer importation and/or batch release - | 17/03/2021   | 01/09/2021   | Annex II and PL          | responsible for Not including batch |
| IB/0004     | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                 | 12/02/2021   | 01/09/2021   | SmPC and PL              |                                     |
| IB/0003     | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                             | 11/01/2021   | n/a          |                          |                                     |
| IB/0002     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following same change for the reference                                                                                                                                                                                                                                                                                                                                                                              | 05/10/2020   | 01/09/2021   | SmPC                     | assessment of the                   |

<div style=\"page-break-after: always\"></div>

|         | product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                     |            |            |             |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| IB/0001 | B.II.a.3.a.1 - Changes in the composition (excipients) of the finished product - Changes in components of the flavouring or colouring system - Addition , deletion or replacement | 09/09/2020 | 01/09/2021 | SmPC and PL |